Literature DB >> 16391186

Quantitative analyses of 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain.

Yota Fujimura1, Yoko Ikoma, Fumihiko Yasuno, Tetsuya Suhara, Miho Ota, Ryohei Matsumoto, Shoko Nozaki, Akihiro Takano, Jun Kosaka, Ming-Rong Zhang, Ryuji Nakao, Kazutoshi Suzuki, Nobumasa Kato, Hiroshi Ito.   

Abstract

UNLABELLED: N-(5-Fluoro-2-phenoxyphenyl)-N-(2-(18)F-fluoroethyl-5-methoxybenzyl)acetamide ((18)F-FEDAA1106) is a potential PET ligand with highly selective and specific binding to peripheral benzodiazepine receptor (PBR). It has been reported that the regional density of PBR in the brain is increased in several neurodegenerative and psychiatric disorders. Thus, a reliable tracer method for evaluating PBR would be of use clinically and for research. To our knowledge, this is the first study to investigate the (18)F-FEDAA1106 binding to PBR in living human brain by PET. We also aimed to evaluate various analytic methods to quantify the density of PBR.
METHODS: PET studies with (18)F-FEDAA1106 were performed on 7 healthy men. Volumes of interest (VOIs) were drawn on PET images. In each VOI, binding potential (BP) was calculated by nonlinear least-squares (NLS) fitting based on the 2-tissue compartment model, and the distribution volume (DV) was also estimated by NLS, Logan plot, and multilinear analysis (MA) methods. To estimate errors in calculation of BP and DV, simulation studies were also performed.
RESULTS: The DVs estimated with each of the methods were significantly correlated. There was also significant correlation between BP with NLS and DV with NLS, Logan plot, or MA. But the interindividual differences in the distribution volume of the free and nonspecific binding compartment (K(1)/k(2)) were relatively large. In a simulation study, variation of the DV estimated by Logan plot was relatively small, but it was underestimated as the noise increased. By MA, the bias of DV was smaller, but the variation of DV was larger than by Logan plot. Within a 3% noise level, there was almost no difference between Logan plot and MA in both bias and variation. DVs estimated by both Logan plot and MA were underestimated by 10%-20%. Although the variation of DV was larger by NLS than by Logan plot, it was small enough in the noise level of VOI analysis, and the bias of DV was 0%-2%.
CONCLUSION: The simulation studies indicated that NLS is a suitable method for the estimation of (18)F-FEDAA1106 binding to PBRs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391186

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  37 in total

1.  Wavelet denoising for voxel-based compartmental analysis of peripheral benzodiazepine receptors with (18)F-FEDAA1106.

Authors:  Miho Shidahara; Yoko Ikoma; Chie Seki; Yota Fujimura; Mika Naganawa; Hiroshi Ito; Tetsuya Suhara; Iwao Kanno; Yuichi Kimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-20       Impact factor: 9.236

Review 2.  Positron emission tomography imaging of neuroinflammation.

Authors:  Annachiara Cagnin; Michael Kassiou; Steve R Meikle; Richard B Banati
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

3.  PET imaging of stroke-induced neuroinflammation in mice using [18F]PBR06.

Authors:  Frederick M Lartey; G-One Ahn; Bin Shen; Keith-Travis Cord; Tenille Smith; Joshua Y Chua; Sahar Rosenblum; Hongguang Liu; Michelle L James; Sophia Chernikova; Star W Lee; Laura J Pisani; Rabindra Tirouvanziam; John W Chen; Theo D Palmer; Frederick T Chin; Raphael Guzman; Edward E Graves; Billy W Loo
Journal:  Mol Imaging Biol       Date:  2013-07-09       Impact factor: 3.488

4.  Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography.

Authors:  Pablo M Rusjan; Alan A Wilson; Peter M Bloomfield; Irina Vitcu; Jeffrey H Meyer; Sylvain Houle; Romina Mizrahi
Journal:  J Cereb Blood Flow Metab       Date:  2011-04-27       Impact factor: 6.200

5.  Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [18F]FEDAA1106: a human whole-body PET study.

Authors:  Akihiro Takano; Balázs Gulyás; Andrea Varrone; Per Karlsson; Nils Sjoholm; Stig Larsson; Cathrine Jonsson; Richard Odh; Richard Sparks; Nabil Al Tawil; Anja Hoffmann; Torsten Zimmermann; Andrea Thiele; Christer Halldin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

6.  Current imaging strategies in rheumatoid arthritis.

Authors:  Merissa N Zeman; Peter Jh Scott
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

7.  In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients.

Authors:  Andrea Varrone; Patrik Mattsson; Anton Forsberg; Akihiro Takano; Sangram Nag; Balázs Gulyás; Jacqueline Borg; Ronald Boellaard; Nabil Al-Tawil; Maria Eriksdotter; Torsten Zimmermann; Marcus Schultze-Mosgau; Andrea Thiele; Anja Hoffmann; Adriaan A Lammertsma; Christer Halldin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

8.  Translocator protein (18 kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [(18)F]-FEPPA.

Authors:  Romina Mizrahi; Pablo M Rusjan; James Kennedy; Bruce Pollock; Benoit Mulsant; Ivonne Suridjan; Vincenzo De Luca; Alan A Wilson; Sylvain Houle
Journal:  J Cereb Blood Flow Metab       Date:  2012-04-04       Impact factor: 6.200

Review 9.  New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease.

Authors:  Laura Best; Christine Ghadery; Nicola Pavese; Yen Foung Tai; Antonio P Strafella
Journal:  Curr Neurol Neurosci Rep       Date:  2019-04-02       Impact factor: 5.081

Review 10.  Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers.

Authors:  Fabien Chauveau; Hervé Boutin; Nadja Van Camp; Frédéric Dollé; Bertrand Tavitian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-01       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.